Jun. 26 at 12:59 PM
$EDSA BARDA ARDS Bull Case Part 2:
The RPP solicitation asks for host-directed therapeutics to prevent progression to ARDS in hospitalized viral respiratory infection patients requiring supplemental oxygen, with a Phase 3 development plan supported by Phase 2 data. Minimum criteria include an active FDA IND for prevention of progression in viral pneumonia, clear relevance to influenza/viral respiratory infections, defined Phase 3 dose selection, and an FDA-aligned Phase 3 design with FDA feedback/concurrence.
The solicitation contemplates roughly
$40–50 million, one award, and a project start in Q4 FY26,
